Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

116 results about "MHC class I" patented technology

MHC class I molecules are one of two primary classes of major histocompatibility complex (MHC) molecules (the other being MHC class II) and are found on the cell surface of all nucleated cells in the bodies of jawed vertebrates. They also occur on platelets, but not on red blood cells. Their function is to display peptide fragments of proteins from within the cell to cytotoxic T cells; this will trigger an immediate response from the immune system against a particular non-self antigen displayed with the help of an MHC class I protein. Because MHC class I molecules present peptides derived from cytosolic proteins, the pathway of MHC class I presentation is often called cytosolic or endogenous pathway.

Tissue MHC class i immunopeptide pattern dedicated for generation of Anti-cancer vaccines against non-small cell lung cancer (NSCLC), identification and isolation of nsclc specific t cells in humans

The invention relates to 2 tissue MHC class I immunopeptide patterns dedicated for generation of anti-cancer vaccines against Non-Small Cell Lung Cancer (NSCLC), identification and isolation of NSCLC specific T cells in humans by antibody-free approach that defined using a list of the 25 quantitative peptides that in NSCLC tumor tissue of patient with healthy tissues are up or down regulated between the comparison of healthy tissue with matched NSCLC patient-derived tissue samples. Therefore, this invention has significant implications for understanding fundamental and applied biological questions.
Owner:UNIV GDANSKI

Methods for expanding t cells

This disclosure relates methods for expanding γδ T cells. More specifically, the disclosure relates to methods of expanding γδ T cells that have an eliminated or reduced expression of endogenous MHC Class I molecules, by expressing a single-chain fusion HLA Class I protein. In some embodiments, the endogenous B2M gene of the γδ T cells is disrupted. In some embodiments, the single-chain fusion HLA Class I protein includes at least a portion of B2M protein and at least a portion of HLA-E heavy chain.
Owner:NANJING LEGEND BIOTECH CO LTD +1

Composition for treating cancer

PCT designated stageWO2025225648A1Organic active ingredientsGenetic material ingredientsMHC class IMHC class II
Provided is a composition for treating cancer in a subject, the composition containing: a nucleic acid which encodes a peptide that includes at least one non-self MHC Class I restricted epitope and at least one non-self MHC Class II restricted epitope; or cells which express the peptide. Also provided is a method comprising analyzing a gene for a cancer tissue obtained from a subject, and determining whether or not a non-self antigen peptide that comprises a non-self amino acid sequence having a longer length than a cut-off value is present in the cancer tissue.
Owner:KYOTO UNIV

MHC class i restricted immunopeptide pattern for generation of Anti-nsclc vaccines

The invention relates to 2 tissue MHC class I immunopeptide patterns dedicated for generation of anti-cancer vaccines against Non-Small Cell Lung Cancer (NSCLC), identification and isolation of NSCLC specific T cells in humans by antibody-free approach that defined using a list of the 25 quantitative peptides that in NSCLC tumor tissue of patient with healthy tissues are up or down regulated between the comparison of healthy tissue with matched NSCLC patient-derived tissue samples. Therefore, this invention has significant implications for understanding fundamental and applied biological questions.
Owner:UNIV GDANSKI

MHC class i chain-related protein a (MICA)-specific antibodies and uses thereof

The present disclosure relates to the treatment of cancer. In particular, the present disclosure provides novel therapeutic antibodies that target MHC Class I Chain-Related Protein A (MICA) in a manner that reduces the ability of a tumor cell to escape immune clearance mediated by the natural killer group 2D (NKG2D) receptor.
Owner:AAKHA BIOLOGICS INC

Methods and compositions for identifying epitopes

Abstract Described herein, in one aspect, are antigen presenting cells (APCs) comprising an exogenous nucleic acid encoding one or more candidate antigens, wherein the one or more candidate antigens are expressed and presented with MHC class I or MC class II molecules; a molecular reporter of Granzyme B (GzB) activity; and c) an exogenous inhibitor of caspase-activated deoxyribonuclease (CAD)-mediated DNA degradation, a CAD knockout, or a caspase knockout (e.g., caspase 3 knockout). Described herein, in another aspect, is a system for detection of recognized antigen presentation by an antigen presenting cell to a cytotoxic lymphocyte or NK cell. Abstract 2018 / 22761 oM - cell Target ml Target cell cell cell Target Target Target SUBSTITUTE SHEET (RULE 26) cell cell cell Target Target cell cell 1 / 28 my Isolate recognized cell Library of target cells target cells and displaying different Add T cells from sample sequence antigens antigens of interest. CTLs deliver cytotoxic granules to target cells displaying cognate antigen FIG. 1 PCT / US2018 / 036663 20 26 20 53 56 07 J ul 2 02 6 2 0 2 6 2 0 5 3 5 6 0 7 J u l 2 0 2 6 2 0 1 8 / 2 2 7 6 1 o M a n d m y 1 / 2 8 m y L i b r a r y o f t a r g e t c e l l s d i s p l a y i n g d i f f e r e n tA d d T c e l l s f r o m s a m p l e of interest. CTLs deliver c y t o t o x i c g r a n u l e s t o t a r g e t c e l l s d i s p l a y i n g c o g n a t e a n t i g e n P C T / U S 2 0 1 8 / 0 3 6 6 6 3
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC

Compositions, systems, and methods for treating cancer using tumor treating fields with inhibitors of MIF, MICA, and / or micb

PCT designated stage expiredWO2025088586A1ElectrotherapyDrug and medicationsMHC class ICancer cell
Compositions, systems, and advanced methods for reducing viability of cancer cells and treating cancer, as well as preventing an increase of volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating field concurrently with administration of at least one composition that inhibits at least one of immunomodulatory cytokine such as (but not limited to) macrophage migration inhibitory factor (MIF), MHC class I chain‐related polypeptide A (MICA), and / or MHC class I chain‐related polypeptide B (MICB).
Owner:BROWN UNIVERSITY +1

Compositions, systems and methods for treating cancer using tumor therapy electric fields in combination with immune checkpoint inhibitors and MHC class I activators

Compositions, systems, and methods are disclosed for reducing the viability of cancer cells and treating cancer, as well as preventing an increase in volume of a tumor present in the body of a living subject. The systems and methods involve applying an alternating field while administering at least one composition that increases the expression of MHC class I molecules in cancer cells.
Owner:NOVOCURE GMBH CH

CD24-expressing cell and applications of the same

To provide a cell including a cell expressing CD24, and related method of use and creation thereof.SOLUTION: Provided is an isolated cell including modification for increasing reduced expression of MHC class I and / or MHC class II human leukocyte antigens and expression of CD24 in a cell. In some embodiments, the cell includes reduced expression of MHC class I and MHC class II human leukocyte antigens.SELECTED DRAWING: None
Owner:SANA BIOTECHNOLOGY INC

Scaffolds with stabilized MHC molecules for immune-cell manipulation

The present invention relates to artificial antigen presenting cell (aAPC) scaffolds to provide cells with specific functional stimulation to obtain phenotypic and functional properties ideal to mediate tumor regression or viral clearance. In particular, the scaffolds of the present invention comprise stabilized MHC class I molecules free of antigenic peptide. The scaffolds can be loaded with antigenic peptide on demand, providing an agile platform for effective expansion and functional stimulation of specific T cells in a peptide-MHC-directed fashion.
Owner:DANMARKS TEKNISKE UNIV

Polynucleotides and lentiviral vectors expressing non-structural antigens of a flavivirus selected from the group of DENV, ZIKV and YFV, inducing protective CD8+ t-cell immunity in a host

The invention relates to recombinant polynucleotides encoding at least a recombinant polynucleotide expressing at least a first fusion polypeptide that comprises MHC class I T-cell epitopes suitable to elicit a T cell immune response in a host in need thereof, wherein the MHC class I T-cell epitopes originate from a plurality of antigens wherein the antigens comprise at least non-structural antigens and are from at least one flavivirus selected from the group of 10 Dengue virus (DENV), ZIKA virus (ZIKV) and Yellow Fever virus (YFV). The invention also relates to the polypeptides comprising polyepitopes of said antigens encoded by the recombinant polynucleotides.
Owner:THERAVECTYS +1

Mouse 4T1 breast cancer therapeutic tumor neoantigen mRNA vaccine as well as preparation method and application thereof

The invention discloses a mouse 4T1 breast cancer therapeutic tumor neoantigen mRNA vaccine and a preparation method and application thereof.The breast cancer therapeutic tumor neoantigen mRNA vaccine comprises an antigen epitope composition, the antigen epitope composition comprises at least one of seven polypeptide fragments combined with MHC class I molecules and three polypeptide fragments combined with MHC class II molecules, and the antigen epitope composition comprises at least one of three polypeptide fragments combined with MHC class II molecules; the amino acid sequences of the seven polypeptide fragments combined with the MHC class I molecules are respectively shown as SEQ ID NO.1-SEQ ID NO.7, and the amino acid sequences of the three polypeptide fragments combined with the MHC class II molecules are respectively shown as SEQ ID NO.8-SEQ ID NO.10. The invention further discloses a preparation method of the polypeptide fragments combined with the MHC class I molecules. The vaccine has an obvious inhibition effect on tumor growth.
Owner:HEFEI AFANA BIOTECHNOLOGY CO LTD

Lung cancer neoantigen polypeptide and its applications

The present invention relates to the technical field of molecular immunology, and specifically discloses novel antigen polypeptides for lung cancer and their applications. The polypeptide comprises one or more amino acid sequences selected from those shown in, for example, PDGPPEKP (SEQ ID NO.1), MNKALLPAK (SEQ ID NO.2), and MYCELPDSF (SEQ ID NO.3); or is a polypeptide with the same or similar function obtained by substituting and / or deleting and / or adding at least one amino acid in the amino acid sequences of the above polypeptides. The novel antigen polypeptide for lung cancer provided by the present invention can bind to MHC class I molecules on human cells, can significantly stimulate the activation and expansion of T lymphocytes with tumor cell killing effects, and increase the killing ability of T cells against lung cancer cells. Therefore, the polypeptide can be used to prepare drugs for treating lung cancer, especially for preparing lung cancer cell vaccines. The antigen polypeptide can be used to treat lung cancer and prevent recurrence and metastasis in patients after surgery.
Owner:JIANGSU OCEAN UNIV +1

Immunization against viral infections disease(s)

The present invention relates to a pharmaceutical composition to prevent or treat viral infection(s), particularly to a combination agent / composition comprising of at least two and most particularly up to 12 different antigen polypeptides corresponding to HLA antigen peptides matching viral epitopes, for immunization against at least one, preferably two, particularly preferably up to 4 viral infectious diseases, a combination preparation (or parts thereof), a method for determining / identifying at least one HLA antigen peptide corresponding to the MHC class I complexes and / or antigen polypeptide for use in the pharmaceutical composition and a method for preparing a pharmaceutical composition comprising at least one antigen polypeptide according to the invention.
Owner:PMCR GMBH

Compositions and methods for allogeneic immune cells

The present disclosure relates to the field of adoptive immune cells, and particularly relates to recombinant nucleic acids encoding molecules to reduce TCR-CD3 complex expression, MHC class I and class II expression, and CD58 expression on immune cells, the use of such nucleic acid molecules and compositions for production of allogeneic immune cells, and pharmaceutical compositions containing the allogeneic immune cells. Also provided are methods for treating cancer.
Owner:CARGO THERAPEUTICS INC

MHC class i molecules

The present disclosure relates to MHC class I molecules, such as HLA-E, and peptide- MHC class I complexes with improved stability and / or refolding yield due to one or more introduced disulphide bridges. The disclosure further provides MHC class I multimers, cells, such as stem cells, comprising said MHC class I molecules, and various methods for their use.
Owner:IMMUDEX APS

MHC class i chain-related protein a (MICA)-specific antibodies and uses thereof

The present disclosure relates to the treatment of cancer. In particular, the present disclosure provides novel therapeutic antibodies that target MHC Class I Chain-Related Protein A (MICA) in a manner that reduces the ability of a tumor cell to escape immune clearance mediated by the natural killer group 2D (NKG2D) receptor.
Owner:AAKHA BIOLOGICS INC

Universal donor cells and related methods

Disclosed herein are universal donor stem cells and cells derived therefrom and methods of their use and production. The universal donor stem cells disclosed herein can be used to overcome allogeneic immune rejection in cell transplantation-based therapies. In certain embodiments, the universal donor cells disclosed herein are pancreatic endoderm cells that do not express one or more MHC-I class cell surface proteins, and the expression of at least one NK activating ligand is disrupted or inhibited.
Owner:VIACYTE INC

NSG mice lacking MHC class I and class II

PendingAU2024204725B2MHC class IHuman tumor
A NOD.Cg-Prkdcscid NSG) mouse which is genetically modified such that the NSG mouse lacks functional major histocompatibility complex I (MHC I) and lacks functional major histocompatibility complex II (MHC II) is provided according to aspects of the present invention. According to specific aspects the genetically modified NSG mouse is a NOD.Cg- Prkdcscid H2-K1tml Bpe H2-Ab1em Mvw H2-D1tml H2rg Wjl / SzJ NSG- RIP-DTR (IAnull) mouse, or a NOD.Cg-B2m'm" Une Prkdcscid H2dlAbl-Ea H2rg!"1 Wjl / SzJ (NSG- B2M ull (IA mouse. Human immune cells and / or human tumor cells are administered to a genetically modified immunodeficient mouse according to aspects described herein and assays of one or more test substances can be performed using the provided mice. 20 24 20 47 25 09 J ul 2 02 4 A B S T R A C T 2 0 2 4 2 0 4 7 2 5 0 9 J u l 2 0 2 4
Owner:JACKSON LAB THE +1

Hypoimmune beta cells differentiated from pluripotent stem cells and related uses and methods

Provided are functional modified stem cell-derived beta (β) cells (SC-beta cells) containing one or more modifications, such as genetic modifications, and related methods of their use and generation. In some embodiments, the modified cells are hypoimmunogenic cells. In some embodiments, the modified SC-beta cells are cells differentiated in vitro from a modified or hypoimmunogenic pluripotent stem cell that contains the one or more modifications. In some embodiments, the one or more modifications reduce or eliminate expression of MHC class I and / or MHC class II human leukocyte antigens and also exogenously express one or more tolerogenic factors such as CD47.
Owner:SANA BIOTECHNOLOGY INC

Genetically engineered nk cells and uses thereof

The present invention relates to genetically engineered NK cells and uses thereof. Specifically provided is a host cell comprising a nucleic acid construct comprising (1) a nucleotide sequence encoding a TCR and a CD8a molecule and (2) a nucleotide sequence encoding a CD3 molecule. The cells produced by the present invention have significant cytotoxicity against specific tumor cells and retain the killing effect of NK cells on tumor cells with down-regulated MHC class I molecules.
Owner:IMMUXELL BIOTECH LTD

Modified cytotoxic t cells and methods of use thereof

The present disclosure provides a modified cytotoxic T cell (mCTL) wherein the mCTL comprises: a) one or more nucleic acids comprising a nucleotide sequence encoding a T cell receptor (TCR) having specificity for an MHC class I polypeptide presenting a human papilloma virus (HPV) E7 peptide comprising the amino acid sequence YMLDLQPETT (SEQ ID NO: 1) or YMLDLQPET (SEQ ID NO: 2); and b) one or more nucleic acids comprising a nucleotide sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen binding domain specific for a cancer-associated antigen. The present disclosure provides a method of producing the mCTL. The present disclosure provides a method of treating cancer comprising administering the mCTL to an individual in need thereof.
Owner:CUE BIOPHARMA INC

Compositions, systems, and methods for treating cancer using tumor treating fields with inhibitors of MIF, MICA, and / or micb

Compositions, systems, and advanced methods for reducing viability of cancer cells and treating cancer, as well as preventing an increase of volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating field concurrently with administration of at least one composition that inhibits at least one of immunomodulatory cytokine such as (but not limited to) macrophage migration inhibitory factor (MIF), MHC class I chain-related polypeptide A (MICA), and / or MHC class I chain-related polypeptide B (MICB).
Owner:BROWN UNIVERSITY +1

A method for screening neoantigen polypeptide sequences of malignant solid tumors

The present invention relates to the technical field of neoantigen screening, and specifically discloses a method for screening neoantigen polypeptide sequences of malignant solid tumors. The method comprises the following steps: obtaining neoantigen prediction results based on HLA class I molecule binding; screening to obtain candidate neoantigen-related mutations; extracting corresponding polypeptide sequences from the neoantigen prediction results to obtain a set of MHC class I potential neoantigen polypeptides; generating all 15-mer sequences centered on the mutation sites and predicting their binding ability to MHC class II molecules to obtain a set of MHC class II potential neoantigen polypeptide sequences; using the maximum margin extension algorithm to obtain long peptide sequences; synthesizing the polypeptide sequences to obtain candidate polypeptide sequences; and evaluating the immunogenicity of the candidate polypeptide sequences to obtain neoantigen polypeptide sequences. The present invention simultaneously considers the binding characteristics of both MHC class I and class II molecules, and can effectively improve the efficiency and accuracy of neoantigen screening.
Owner:TIANJIN CANCER HOSPITAL AIRPORT HOSPITAL +1

A screening method for atypical new antigens

The present invention discloses a method for screening atypical neoantigens, comprising: an RNA-seq screening step: an HLA typing prediction step: a gene transcript expression quantification step: a transcript variable splicing mutation detection step: an RNA editing mutant peptide generation step; a reference mutant peptide data construction step; a neoantigen prediction step: combining the results obtained in the HLA typing prediction step to obtain the binding affinity of candidate neoantigens to MHC class I and the binding affinity to MHC class II; obtaining atypical neoantigens by sorting candidate neoantigens; the screening method, through RNA-seq data of tumor patients, combined with bioinformatics tools, utilizes the characteristics that effective neoantigens have similar sequences, and shares neoantigens between patients with the same disease.
Owner:GZ RUNSHENG CYTOMED TECH CO LTD

Systems and methods for chaperone-mediated ligand exchange on MHC-i and MHC-related molecules using chicken tapbpr

This invention relates to ligand exchange proteins comprising the luminal domain of TAP-binding protein-related (TAPBPR), which functions as a MHC class I ligand-exchange catalyst when presented to mammalian cells either as a soluble extracellular protein or as a membrane bound cell surface protein. This may be useful in modulating immune responses, including for example loading immunogenic ligand onto tumors or other disease cells to induce their recognition by T cells. Ligand-exchange proteins and methods for their use are provided. The invention further relates to an approach for generating conditional peptide ligands for a range of disease-related MHC-I allotypes. The present invention relates to chicken and human TAPBPRs and tapasins as well as orthologs thereof, derivatives thereof, and any mutants thereof as well as any combinations thereof. The present invention also relates to placeholder conditional ligands for ligand-exchange reactions across multiple HLA allotypes.
Owner:THE CHILDRENS HOSPITAL OF PHILADELPHIA +1

Method of use for benzofuran compounds

An orally bioavailable benzofuran is provided which possesses in vitro and in vivo capabilities able to overcome issues in loading of antigenic peptide on major histocompatibility class I complexes, including on the surface of professional antigen presenting cells. The design of immunotherapies such as dendritic cell vaccines, optimal binding of the antigenic peptides to MHC class I complexes is a major challenge. Current therapeutic peptide loading is expensive, labor-intensive, or requires in vitro manipulation. Models demonstrate that the benzofuran enhances T-cell activation through increased peptide binding to cell surface MHC class I complexes. Molecular docking studies indicate the benzofuran binds the F pocket of MHC class I in a similar manner to high-affinity peptides and TAPBPR, aiding in the targeted loading of exogenous peptides. The therapeutic potential was demonstrated when using PLGA particles of BzFβ were injected intramuscularly, and significantly inhibited the development of E.G7-OVA tumors.
Owner:TAMPA BAY RES INST

Transgenic mouse model expressing human hla-a201 restricted genes

ActiveCN116322317BTransferasesVector-based foreign material introductionMHC class IImmunodeficient mouse model
The present disclosure provides immunodeficient NOD.Cg-Prkdc scid Il2rg tm1Wjl / SzJ (NSG TM ) mouse models comprising an inactivated mouse Flt3 allele, a nucleic acid encoding human interleukin 3 (IL3), a nucleic acid encoding human granulocyte / macrophage stimulating factor (GM-CSF), a nucleic acid encoding human stem cell factor (SCF), and an HLA-A2 / H2-D / B2M transgene encoding (i) human B2 microglobulin (B2M) covalently linked to the MHC class I, alpha 1 and alpha 2 binding domains of the human HLA-A2.1 gene and (ii) the alpha 3 cytoplasmic and transmembrane domains of murine H2-Db.
Owner:JACKSON LAB THE